DERM
DERM clinical trials: Journey Medical Corp
Every trial on ClinicalTrials.gov where Journey Medical Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 10
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
DERM on the catalyst calendar · DERM registry changes
- Primary completion Jan 2015ActualPhase 2NCT02129660Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary HyperhidrosisJourney Medical Corporation · HyperhidrosisCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2023ActualPhase 3NCT05343455A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)Journey Medical Corporation · Papulopustular RosaceaCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2023ActualPhase 3NCT05296629A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.Journey Medical Corporation · Papulopustular RosaceaCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2023ActualPhase 1NCT05597462Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 WeeksJourney Medical Corporation · RosaceaCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 25, 2022ActualPhase 1NCT05452785A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy...Journey Medical Corporation · PharmacokineticsCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2019ActualPhase 2NCT03880266A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar HyperhidrosisJourney Medical Corporation · Palmar HyperhidrosisCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 3NCT02553798Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary HyperhidrosisJourney Medical Corporation · HyperhidrosisCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2016ActualPhase 3NCT02530294Study of Glycopyrronium in Subjects With Axillary HyperhidrosisJourney Medical Corporation · HyperhidrosisCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2016ActualPhase 3NCT02530281Study of Glycopyrronium in Axillary HyperhydrosisJourney Medical Corporation · HyperhidrosisCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2014ActualPhase 2NCT02016885A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary HyperhidrosisJourney Medical Corporation · HyperhidrosisCompletedDERMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimateEarly Phase 1NCT07462702Topical Minocycline for CARPMedical University of South Carolina · Confluent and Reticulated Papillomatosis (CARP)Not yet recruitingDERMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner